Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub in the scientific planning and organization of program projects, collaborations, and activities. His research efforts focus on developing systematic approaches to map the function of genes that are mutated in tumors.
Previously, Boehm worked for three and a half years as a research scientist in the Broad Cancer Program. In this role he managed several large, collaborative research efforts that spanned multiple platforms, programs and initiatives at the Broad Institute and Dana-Farber Cancer Institute. These included the generation of functional genomics tools for the community as well as the deployment of these tools in systematic, high-throughput experiments to determine the function of elements in the cancer genome.
Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the laboratory of William Hahn at the Dana-Farber Cancer Institute, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous.Select Publications
Boehm JS et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007 Jun 15;129(6):1065-79.
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 5;462(7269):108-12.
Johannessen CM, Boehm JS, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16;468(7326):968-72.
Cheung HW, Cowley GS, Weir BA, Boehm JS, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. PNAS. 2011 Jul;108(30):1272-7. DOI:10.1073/pnas.1109363108